We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Innovative Spinal Facet Replacement System

By HospiMedica staff writers
Posted on 05 May 2008
A new orthopedic facet replacement system treating spinal stenosis replaces degenerative facet joints with a prosthetic joint implant intended to restore stability and normal motion to the spine, eliminating the need for fusion.

The Archus Total Facet Arthroplasty System (TFAS)-C system is indicated for the L3-4 and L4-5 spinal levels, and it complements the company's TFAS-LS system, which addresses the unique anatomy of the L5-S1, the lumbosacral spinal level. More...
Both systems are part of TFAS, a modular implantable device that is intended to replace the facets and excised elements of the posterior lumbar spine following facetectomy and neural decompressive procedures. Implanted via an open posterior surgical approach, TFAS-C is fixed within the pedicles and it provides immediate alignment and stabilization of the spinal segment at a single spinal level (L3-L4 or L4-L5), while maintaining anatomical ranges of motion. The system is comprised of implantable grade metal components offered in a range of sizes to address the specific anatomical requirements of each patient. Implant component selection is made based upon preoperative imaging measurements and intraoperative trialing. Pedicle fixation of TFAS components is accomplished via the use of polymethylmethacrylate (PMMA) containing 30% barium sulphate. A specialized set of instruments facilitates implantation of the TFAS components. The TFAS modules, developed by Archus Orthopedics (Redmond, WA, USA), have been successfully implanted in nearly two hundred patients worldwide, with the vast majority treated in the United States in an ongoing investigational device exemption (IDE) study approved by the U.S. Food and Drug Administration (FDA).

”The TFAS-C completes our spinal stenosis product line and it is gratifying to see all three devices now in clinical use,” said Jim Fitzsimmons, chairman and CEO of Archus Orthopedics. "We expect to complete marketing trials this year and plan to pursue a broad but controlled launch in Europe next year.”

"The full product line that Archus has developed for spinal stenosis allows me to treat almost all comers and gives me multiple device options to address variable patient anatomy and pathology,” added Scott Webb, M.D., a spine surgeon at the Florida Spine Institute (Clearwater, USA) who performed the first TFAS implantation in 2005, which was one of the earliest facet joint replacement procedures ever completed.


Related Links:
Archus Orthopedics
Florida Spine Institute

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.